Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Dec;13(12):1173-4.
doi: 10.1016/S1470-2045(12)70460-6. Epub 2012 Nov 9.

Abiraterone acetate: a hat trick of clinical benefits

Michael T Schweizer  1 , Emmanuel S Antonarakis
Affiliations
Comment

Abiraterone acetate: a hat trick of clinical benefits

Michael T Schweizer et al. Lancet Oncol. 2012 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare that we have no conflicts of interest.

Comment on

References

    1. Oudard S, Banu E, Medioni J, et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 2009;103:1641–1646. - PubMed
    1. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 published online Nov 9. http://dx.doi.org/10.1016/S1470-2045(12)70473-4. - DOI - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154. - PubMed

MeSH terms